Publication of eQUEST Study Results Demonstrate that eSight 3 is a Clinically Effective Device for the Visually Impaired
TORONTO and LOS ANGELES – September 04, 2018 — Dr. Brian Mech, President and CEO of eSight, is proud to announce the publication of results from eQUEST (The eSight Quality of Life and Efficacy Study), a multi-center, clinical study, conducted independently at six preeminent low-vision research and rehabilitation institutions in the United States and Canada. Results for the study group of 51 subjects substantiate the real life improvements in functional vision observed across thousands of low vision individuals who wear eSight electronic glasses, and are to be published in the September 2018 issue of Optometry and Vision Science.
To view the article in full, including abstract, please visit the Optometry and Vision Science website: The Effect of a Head-mounted Low Vision Device on Visual Function.
“The results from eQUEST represent clinical validation of our life changing wearable technology, which is the cornerstone of our mission at eSight,” said Dr. Mech. “We are absolutely thrilled to share these results with customers and clinicians alike, and we are confident that research will continue to prove eSight is unparalleled in what it can offer in terms of quality of life and functional sight enhancement for the visually impaired.”
“For us, this is more than an expected outcome,” he continued. “This is an affirmation of over twelve years and tens of millions of dollars in research and development, and a milestone for both our company and the visually impaired community that we are dedicated to empowering.”
The study was conducted by following 51 individuals with low-vision, using a comprehensive set of tests both prior to, and after being fitted with eSight’s electronic glasses. In addition, individuals were tested after 3 months of at-home use of eSight. The results were overwhelmingly positive, demonstrating significant improvements in objective visual function measures, Activities of Daily Living and, most importantly, patient-reported quality of life outcomes.
Notably, patients did not experience a decline in mobility performance, which is a significant drawback of other wearable assistive technologies for the visually impaired.
According to Dr. Walter Wittich, PhD at Université de Montréal, the main author of the study, “eSight resulted in immediate improvements in all visual function measures, with face recognition and activities of daily life showing a benefit of further practice and training. Self-reported outcomes suggest that visual abilities, such as reading, are greatly improved when wearing the device.”
This transformative study further validates the work that eSight has been doing to make a meaningful difference in the lives of the low-vision community. eSight is also marking the publication of eQUEST with the launch of a Clinical Consultation Program that will connect eye care professionals and their low-vision patients with this breakthrough technology.
eSight is an organization with a simple but profound promise: To help people see the world, and change the world. A unique and patented technology, eSight 3 are electronic glasses which enable people with vision loss to independently carry out virtually all Activities of Daily Living. eSight is registered with the FDA and EUDAMED, and is inspected by Health Canada. It is available globally. Find us at www.eSightEyewear.com, Twitter, LinkedIn and Facebook.
Contact: Eric Down, Special Projects Coordinator
Phone: +1 (343) 363-4438